Laurence Camoin-Jau

List of Publications by Year
in descending order

71 papers	3,134 citations	304743 22 h-index	155660 55 g-index
81 all docs	81 docs citations	81 times ranked	3825 citing authors

#	Article	IF	Citations
1	Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance. Journal of the American College of Cardiology, 2008, 51, 1404-1411.	2.8	531
2	Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis. American Journal of Cardiology, 2009, 103, 5-10.	1.6	271
3	Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 872-877.	2.8	247
4	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Medicine and Infectious Disease, 2020, 36, 101791.	3.0	209
5	High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2011, 58, 467-473.	2.8	196
6	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. American Journal of Cardiology, 2008, 101, 1088-1093.	1.6	194
7	Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood, 2007, 110, 2432-2439.	1.4	181
8	Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thrombosis and Haemostasis, 2010, 104, 456-463.	3.4	153
9	Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19*2Loss of Function Polymorphism. Journal of the American College of Cardiology, 2010, 56, 1630-1636.	2.8	110
10	Natural history of COVID-19 and therapeutic options. Expert Review of Clinical Immunology, 2020, 16, 1159-1184.	3.0	101
11	High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Critical Care, 2011, 15, R31.	5.8	80
12	Relation of Body Mass Index to High On-Treatment Platelet Reactivity and of Failed Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2009, 104, 1511-1515.	1.6	78
13	TRAIL/Apo2L Mediates the Release of Procoagulant Endothelial Microparticles Induced by Thrombin In Vitro. Circulation Research, 2009, 104, 943-951.	4.5	72
14	Heparin-Induced Thrombocytopenia in Severe COVID-19. Circulation, 2020, 142, 1875-1877.	1.6	62
15	Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thrombosis Research, 2010, 126, e147-e149.	1.7	37
16	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions, 2017, 10, 2560-2570.	2.9	36
17	Comparison Between ESC and Duke Criteria for the Diagnosis of Prosthetic Valve Infective Endocarditis. JACC: Cardiovascular Imaging, 2020, 13, 2605-2615.	5.3	35
18	Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. American Journal of Cardiology, 2011, 108, 1710-1713.	1.6	34

#	Article	IF	Citations
19	Intracranial haemorrhage in infective endocarditis. Archives of Cardiovascular Diseases, 2018, 111, 712-721.	1.6	33
20	Coronary events complicating infective endocarditis. Heart, 2017, 103, 1906-1910.	2.9	28
21	Level of Adenosine Diphosphate Receptor P2Y12 Blockade During Percutaneous Coronary Intervention Predicts the Extent of Endothelial Injury, Assessed by Circulating Endothelial Cell Measurement. Journal of the American College of Cardiology, 2010, 56, 1024-1031.	2.8	27
22	Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets, 2010, 21, 503-507.	2.3	27
23	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. Thrombosis and Haemostasis, 2012, 108, 101-106.	3.4	22
24	Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. Reviews in Cardiovascular Medicine, 2021, 22, 1063.	1.4	21
25	Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thrombosis Research, 2010, 125, e167-e170.	1.7	20
26	Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF. Human Reproduction, 2007, 22, 2261-2266.	0.9	19
27	Thrombosis and antiphospholipid antibody syndrome during acute Q fever. Medicine (United States), 2017, 96, e7578.	1.0	19
28	Aspirin Effect on Staphylococcus aureusâ€"Platelet Interactions During Infectious Endocarditis. Frontiers in Medicine, 2019, 6, 217.	2.6	19
29	Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 2015, 114, 702-707.	3.4	18
30	Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria. Frontiers in Pharmacology, 2020, 11, 863.	3.5	17
31	Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. Thrombosis and Haemostasis, 2010, 104, 410-411.	3.4	14
32	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. International Journal of Cardiology, 2013, 168, 4244-4248.	1.7	14
33	Spondylodiscitis complicating infective endocarditis. Heart, 2020, 106, 1914-1918.	2.9	13
34	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thrombosis Research, 2012, 130, 70-74.	1.7	12
35	Different pattern of the second outbreak of COVID-19 in Marseille, France. International Journal of Infectious Diseases, 2021, 102, 17-19.	3.3	12
36	18F-fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of native valve infective endocarditis: A prospective study. Archives of Cardiovascular Diseases, 2021, 114, 211-220.	1.6	12

#	Article	IF	Citations
37	Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2âž loss of function polymorphism. International Journal of Cardiology, 2010, 145, 165-166.	1.7	11
38	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. International Journal of Cardiology, 2016, 220, 496-500.	1.7	11
39	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. Frontiers in Medicine, 2020, 7, 599626.	2.6	11
40	Infective endocarditis with neurological complications: Delaying cardiac surgery is associated with worse outcome. Archives of Cardiovascular Diseases, 2021, 114, 527-536.	1.6	10
41	Effect of antiplatelet agents on platelet antistaphylococcal capacity: An in vitro study. International Journal of Antimicrobial Agents, 2020, 55, 105890.	2.5	9
42	A Novel Approach for Detecting Unique Variations among Infectious Bacterial Species in Endocarditic Cardiac Valve Vegetation. Cells, 2020, 9, 1899.	4.1	9
43	Single or triple positivity for antiphospholipid antibodies in â€œcarriersâ€•or symptomatic patients: Untangling the knot. Journal of Thrombosis and Haemostasis, 2021, 19, 3018-3030.	3.8	9
44	The distinct effects of aspirin on platelet aggregation induced by infectious bacteria. Platelets, 2020, 31, 1028-1038.	2.3	8
45	Statins potentiate the antibacterial effect of platelets on Staphylococcus aureus. Platelets, 2021, 32, 671-676.	2.3	8
46	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. Journal of Thrombosis and Haemostasis, 2018, 16, 465-473.	3.8	7
47	Platelets and Escherichia coli: A Complex Interaction. Biomedicines, 2022, 10, 1636.	3.2	6
48	Comparing two blood culture systems for the detection of bacterial contamination in platelet concentrates. Transfusion, 2018, 58, 2604-2610.	1.6	5
49	Clinical validation of immunoassay HemosILÂ® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2021, 52, 601-609.	2.1	5
50	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. Journal of Microbiology, Immunology and Infection, 2021, 54, 37-45.	3.1	5
51	Case series of massive direct oral anticoagulant ingestionâ€”Treatment and pharmacokinetics data. European Journal of Clinical Investigation, 2022, , e13746.	3.4	5
52	Enhanced Prevalence of Plasmatic Soluble MHC Class I Chain-Related Molecule in Vascular Pregnancy Diseases. BioMed Research International, 2014, 2014, 1-11.	1.9	4
53	Ultrastructure of a late-stage bacterial endocarditis valve vegetation. Journal of Thrombosis and Thrombolysis, 2021, 51, 821-826.	2.1	4
54	The Antibacterial Effect of Platelets on Escherichia coli Strains. Biomedicines, 2022, 10, 1533.	3.2	4

#	Article	IF	Citations
55	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. Platelets, 2019, 30, 105-111.	2.3	3
56	Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy. Journal of Clinical Medicine, 2021, 10, 1565.	2.4	3
57	In vitro detection of bacterial contamination in platelet concentrates by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: a preliminary study. Journal of Medical Microbiology, 2017, 66, 1523-1530.	1.8	3
58	Platelets and endothelium: Two key players in percutaneous coronary intervention. Archives of Cardiovascular Diseases, 2011, 104, 601-603.	1.6	2
59	Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?. Current Pharmaceutical Design, 2012, 18, 5392-5401.	1.9	2
60	Platelet Reactivity. Journal of the American College of Cardiology, 2017, 69, 114.	2.8	2
61	Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery. Annals of Thoracic Surgery, 2017, 103, e9-e10.	1.3	2
62	Rapid identification of microorganisms from platelet concentrates by matrixâ€assisted laser desorption ionization timeâ€ofâ€flight mass spectrometry after shortâ€term incubation on liquid medium. Transfusion, 2018, 58, 766-773.	1.6	2
63	Drug Response Diversity: A Hidden Bacterium?. Journal of Personalized Medicine, 2021, 11, 345.	2.5	2
64	Mitral valve repair is better than mitral valve replacement in native mitral valve endocarditis: Results from a prospective matched cohort. Archives of Cardiovascular Diseases, 2022, 115, 160-168.	1.6	2
65	Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. Expert Review of Cardiovascular Therapy, 2009, 7, 1525-1532.	1.5	1
66	Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Hospital Practice (1995), 2012, 40, 104-117.	1.0	1
67	Factor VIII:C levels in pregnancies complicated by preâ€eclampsia and intrauterine growth restriction. International Journal of Gynecology and Obstetrics, 2012, 116, 258-259.	2.3	1
68	Biological efficacy and clinical safety of a second 600 mg loading dose of clopidogrel in elderly patients with high on-treatment platelet reactivity: A pilot study. International Journal of Cardiology, 2013, 165, 200-201.	1.7	1
69	A threshold of platelet reactivity for ischaemic events?. European Heart Journal, 2008, 29, 2185-2186.	2.2	0
70	TCT-737 Relationship between post treatment platelet reactivity and ischemic and bleeding events at one year follow-up in acute coronary syndrome patients receiving prasugrel. Journal of the American College of Cardiology, 2012, 60, B215.	2.8	0
71	The hidden side of oral thrombin inhibitors. International Journal of Cardiology, 2019, 274, 186-187.	1.7	0